Poster Session A - Sunday Afternoon
Category: Colon
Darren M. Brenner, MD, FACG
Northwestern University Feinberg School of Medicine
Chicago, IL
Placebo (N=363)a n (%) | Naloxegol 12.5 mg (N=352)a n (%) | Naloxegol 25 mg (N=336)a n (%) | Naloxegol 12.5 mg vs. Placebo OR (95% CI) p-value | Naloxegol 25 mg vs. Placebo OR (95% CI) p-value |
Proportion of PAC-QOL Responders Achieving MCID > 0.5 | ||||
214 (58.95%) | 241 (68.47%) | 222 (66.07%) | 1.500 (1.077, 2.089) 0.0165 | 1.395 (1.004, 1.938) 0.0471 |
Proportion of PAC-QOL Responders Achieving MCID > 0.8 | ||||
166 (45.73%) | 198 (56.25%)` | 177 (52.68%) | 1.517 (1.103, 2.087) 0.0104 | 1.348 (0.978, 1.858) 0.0682 |
aNumber of analyzable subjects with complete PAC-QOL data for 12-wks PAC-QOL, Patient Assessment of Constipation Quality of Life questionnaire MCID, minimal clinically important difference OR, odds ratio CI, confidence interval |